For endocarditis or bloodstream infection: 6-10mg/kg IV daily For non-bloodstream infections: 4mg/kg IV daily
Unknown for severe hepatic dysfunction
Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC>=2) and VRE including endovascular infection
Creatine kinase weekly.
Myopathy including rhabdomyolysis, GI side effects common, rash, phlebitis, increased INR
Statins and fibrates: monitor creatine kinase or hold while on daptomycin therapy (increased myopathy)
Mandatory ID consult for use in PHC.
Higher doses used for endovascular infection.
Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.
Antimicrobial class: Cyclic lipopeptide, depolarizes bacterial cell membrane
Pregnancy category: B
Average serum half life: 9.0
CSF penetration: Poor
Urine penetration: Therapeutic
Lung penetration: Poor